Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Other Non-Current Assets (2016 - 2025)

Spero Therapeutics (SPRO) has disclosed Other Non-Current Assets for 10 consecutive years, with $153000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Non-Current Assets changed 0.0% year-over-year to $153000.0, compared with a TTM value of $153000.0 through Sep 2025, changed 0.0%, and an annual FY2024 reading of $153000.0, down 64.83% over the prior year.
  • Other Non-Current Assets was $153000.0 for Q3 2025 at Spero Therapeutics, roughly flat from $153000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $5.9 million in Q1 2022 and bottomed at $153000.0 in Q3 2024.
  • Average Other Non-Current Assets over 5 years is $3.1 million, with a median of $5.2 million recorded in 2021.
  • The sharpest move saw Other Non-Current Assets rose 13.76% in 2022, then plummeted 92.44% in 2024.
  • Year by year, Other Non-Current Assets stood at $5.6 million in 2021, then grew by 1.7% to $5.7 million in 2022, then tumbled by 92.42% to $435000.0 in 2023, then tumbled by 64.83% to $153000.0 in 2024, then changed by 0.0% to $153000.0 in 2025.
  • Business Quant data shows Other Non-Current Assets for SPRO at $153000.0 in Q3 2025, $153000.0 in Q2 2025, and $153000.0 in Q1 2025.